Anavex Gets FDA Go-Ahead For Fragile X Study Of Blarcamesine, Now Has Three Open Applications
The company plans a Phase 2a study in about 60 adult males, and its applications in Alzheimer's, Rett syndrome and Fragile X are now all open.
The FDA told Anavex it may proceed with a planned clinical study of blarcamesine in Fragile X syndrome, the company said in an 8-K filed Thursday. The application is now open, which gives Anavex open applications in Alzheimer's disease, Rett syndrome and Fragile X.
What the press release says
The 8-K attaches a press release saying the FDA cleared the company's investigational new drug application, the filing that permits testing of a drug in people. Fragile X is a genetic condition the company describes as the most common inherited cause of intellectual disability, with no FDA-approved treatment.
The planned Phase 2a (mid-stage) study is called ANAVEX2-73-FXS-001. It is randomized, double-blind and compared against a placebo group, with dose-ranging, and would enroll approximately 60 adult males. Its main focus is safety, tolerability and how the body processes the oral solution. Behavioral and cognitive measures are secondary endpoints.
Interim CEO Terrie Kellmeyer called the clearance "an important milestone that gives Anavex open INDs in all three of our core indications: Alzheimer's Disease, Rett syndrome, and Fragile X syndrome."
The evidence behind it, and the limits
The program rests on mouse work. Blarcamesine has been tested in the Fmr1 knockout mouse model of Fragile X in three peer-reviewed publications, the latest in Frontiers in Pharmacology in September 2026. That paper extended preliminary data Anavex reported in 2024: 14 days of oral dosing produced dose-related improvement in EEG abnormalities that the mice share with people who have the condition.
The drug already holds FDA Orphan Drug Designation for Fragile X. The company also states that blarcamesine is unapproved for any indication and that its safety and efficacy in Fragile X have not been established.
The company cites National Fragile X Foundation estimates of diagnosis in 1 in 7,000 males and 1 in 11,000 females.
What to watch
Site activation and enrollment. The company's forward-looking statements say the study may not start or finish on schedule, citing possible delays in site activation, institutional review board approvals and patient recruitment.
Anavex shares closed at $1.48 in Thursday's regular session and were at $1.47 in Thursday after-hours trading, according to market data.
The company's own risk language names site activation, review board approvals and patient recruitment as the points where the Phase 2a timeline could slip.
Sources
- 8-K Filing — ANAVEX LIFE SCIENCES CORP. (AVXL) — SEC EDGAR
- Exhibit e8009_ex99-1.htm — ANAVEX LIFE SCIENCES CORP. 8-K exhibit — SEC EDGAR